FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 330:1114-1118 April 21, 1994 Number 16 Next

	Full Text Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

ABSTRACT

Background As maternal age advances, the risk of fetal Down's syndrome increases. Pregnant women 35 years of age or older are routinely offered amniocentesis because of this risk. Recently, maternal serum markers have been reported to be useful in screening for Down's syndrome, primarily in younger women. We therefore investigated whether offering amniocentesis only to selected women 35 years of age or older who were identified by screening measurements in serum might prove a useful alternative to the current practice.

Methods We studied 5385 women with singleton pregnancies who were 35 years of age or older and were undergoing routine amniocentesis. Along with information about the pregnancy, we obtained a serum sample for measurement of alpha-fetoprotein, unconjugated estriol, and human chorionic gonadotropin. Individual estimates of the risk of Down's syndrome in the fetus were calculated for each pregnancy before the karyotype was known.

Results If amniocentesis had been reserved for the women calculated to have a risk greater than 1 in 200 of having a fetus with Down's syndrome, 48 of the 54 cases of Down's syndrome (89 percent) would have been identified; 25 percent of the unaffected pregnancies would also have been identified as being at high risk for Down's syndrome (false positives). Seven of 15 fetuses (47 percent) with other trisomies, 11 of 25 (44 percent) with sex aneuploidy, and 1 of 9 (11 percent) with miscellaneous chromosomal abnormalities would also have been detected. In practice, such screening would have made 75 percent of the amniocenteses unnecessary, along with a proportion of the amniocentesis-associated fetal losses. If the cutoff for the risk of Down's syndrome were set higher than 1 in 200, both the rate of detection and the false positive rate would be lower. Conversely, these rates would be higher if the cutoff were set lower.

Conclusions Prenatal screening of serum to generate individual estimates of the risk of Down's syndrome in the fetus can provide a basis for decision making in the cases of women 35 years of age or older, as it does in younger pregnant women, and is an alternative to current testing practices. .

Source Information

From the Foundation for Blood Research, Scarborough, Me. (J.E.H., G.E.P., G.J.K.); the California Department of Health Services, Genetic Disease Branch, Berkeley (G.C.C., L.S.L.); and the California Public Health Foundation, Berkeley (P.A.B.).

Address reprint requests to Dr. Haddow at the Foundation for Blood Research, Scarborough, ME 04074.

Full Text of this Article

Related Letters:

Triple-Marker Screening of Serum for Down's Syndrome
Herrmann J., Haddow J. E., Palomaki G. E.
Extract | Full Text  
N Engl J Med 1994; 331:681-682, Sep 8, 1994. Correspondence

This article has been cited by other articles:

• Kuppermann, M., Learman, L. A., Gates, E., Gregorich, S. E., Nease, R. F. Jr, Lewis, J., Washington, A. E. (2006). Beyond Race or Ethnicity and Socioeconomic Status: Predictors of Prenatal Testing for Down Syndrome.. Obstet Gynecol 107: 1087-1097 [Abstract] [Full Text]  
• Nicolini, U., Lalatta, F., Natacci, F., Curcio, C., Bui, T.-H. (2004). The introduction of QF-PCR in prenatal diagnosis of fetal aneuploidies: time for reconsideration. Hum Reprod Update 10: 541-548 [Abstract] [Full Text]  
• Palomaki, G. E., Neveux, L. M., Knight, G. J., Haddow, J. E., Pandian, R. (2004). Maternal Serum Invasive Trophoblast Antigen (Hyperglycosylated hCG) as a Screening Marker for Down Syndrome during the Second Trimester. Clin. Chem. 50: 1804-1808 [Abstract] [Full Text]  
• Benn, P. A., Egan, J. F. X., Fang, M., Smith-Bindman, R. (2004). Changes in the Utilization of Prenatal Diagnosis. Obstet Gynecol 103: 1255-1260 [Abstract] [Full Text]  
• DeVore, G. R., Romero, R. (2003). Genetic Sonography: An Option for Women of Advanced Maternal Age With Negative Triple-Marker Maternal Serum Screening Results. J Ultrasound Med 22: 1191-1199 [Abstract] [Full Text]  
• Wapner, R., Thom, E., Simpson, J. L., Pergament, E., Silver, R., Filkins, K., Platt, L., Mahoney, M., Johnson, A., Hogge, W. A., Wilson, R. D., Mohide, P., Hershey, D., Krantz, D., Zachary, J., Snijders, R., Greene, N., Sabbagha, R., MacGregor, S., Hill, L., Gagnon, A., Hallahan, T., Jackson, L., the First Trimester Maternal Serum Biochemistry an, (2003). First-Trimester Screening for Trisomies 21 and 18. NEJM 349: 1405-1413 [Abstract] [Full Text]  
• Vintzileos, A. M., Guzman, E. R., Smulian, J. C., Yeo, L., Scorza, W. E., Knuppel, R. A. (2002). Second-Trimester Genetic Sonography in Patients With Advanced Maternal Age and Normal Triple Screen. Obstet Gynecol 99: 993-995 [Abstract] [Full Text]  
• Reis, F. M., D'Antona, D., Petraglia, F. (2002). Predictive Value of Hormone Measurements in Maternal and Fetal Complications of Pregnancy. Endocr. Rev. 23: 230-257 [Abstract] [Full Text]  
• DeVore, G. R., Romero, R. (2002). Genetic Sonography: A Cost-effective Method for Evaluating Women 35 Years and Older Who Decline Genetic Amniocentesis. J Ultrasound Med 21: 5-13 [Abstract] [Full Text]  
• ZOPPI, M. A., IBBA, R. M., PUTZOLU, M., FLORIS, M., MONNI, G. (2001). Nuchal Translucency and the Acceptance of Invasive Prenatal Chromosomal Diagnosis in Women Aged 35 and Older. Obstet Gynecol 97: 916-920 [Abstract] [Full Text]  
• EGAN, J. F. X., BENN, P., BORGIDA, A. F., RODIS, J. F., CAMPBELL, W. A., VINTZILEOS, A. M. (2000). Efficacy of Screening for Fetal Down Syndrome in the United States From 1974 to 1997. Obstet Gynecol 96: 979-985 [Abstract] [Full Text]  
• KUPPERMANN, M., NEASE, R. F. Jr, LEARMAN, L. A., GATES, E., BLUMBERG, B., WASHINGTON, A. E. (2000). Procedure-Related Miscarriages and Down Syndrome-Affected Births: Implications for Prenatal Testing Based on Women's Preferences. Obstet Gynecol 96: 511-516 [Abstract] [Full Text]  
• Goshen, R. (1999). What factors regulate HCG production in Down's syndrome pregnancies?: Screening for Down's syndrome using HCG concentrations - a common practice but still and enigma. Mol Hum Reprod 5: 893-895 [Full Text]  
• Wyllie, J. P, Madar, R J., Wright, M., Burn, J., Wren, C. (1997). Strategies for antenatal detection of Down's syndrome. Arch. Dis. Child. Fetal Neonatal Ed. 76: 26F-30 [Abstract] [Full Text]  
• Herrmann, J., Haddow, J. E., Palomaki, G. E. (1994). Triple-Marker Screening of Serum for Down's Syndrome. NEJM 331: 681-682 [Full Text]  
• (1994). A NEW SCREENING STRATEGY FOR DOWN'S SYNDROME. JWatch General 1994: 1-1 [Full Text]  
• Pauker, S. P., Pauker, S. G. (1994). Prenatal Diagnosis -- Why Is 35 a Magic Number?. NEJM 330: 1151-1152 [Full Text]  
• Caughey, A. B., Washington, A E., Gildengorin, V., Kuppermann, M. (1980). Assessment of Demand for Prenatal Diagnostic Testing Using Willingness to Pay. Obstet Gynecol 103: 539-545 [Abstract] [Full Text]